221 related articles for article (PubMed ID: 21541781)
1. Macitentan: entry-into-humans study with a new endothelin receptor antagonist.
Sidharta PN; van Giersbergen PL; Halabi A; Dingemanse J
Eur J Clin Pharmacol; 2011 Oct; 67(10):977-84. PubMed ID: 21541781
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
Sidharta PN; van Giersbergen PL; Dingemanse J
J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
[TBL] [Abstract][Full Text] [Related]
4. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
Sidharta PN; van Giersbergen PL; Wolzt M; Dingemanse J
Br J Clin Pharmacol; 2014 Nov; 78(5):1035-42. PubMed ID: 24962473
[TBL] [Abstract][Full Text] [Related]
5. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
Sidharta PN; Melchior M; Kankam MK; Dingemanse J
Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex.
Bruderer S; Marjason J; Sidharta PN; Dingemanse J
Pharmacology; 2013; 91(5-6):331-8. PubMed ID: 23817130
[TBL] [Abstract][Full Text] [Related]
7. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
van Giersbergen PL; Dingemanse J
Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects.
Sidharta PN; Dietrich H; Dingemanse J
Clin Drug Investig; 2014 Aug; 34(8):545-52. PubMed ID: 24861134
[TBL] [Abstract][Full Text] [Related]
9. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.
Lindegger N; Sidharta PN; Reseski K; Dingemanse J
Pulm Pharmacol Ther; 2014 Oct; 29(1):41-8. PubMed ID: 24813561
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy Subjects.
Issac M; Dingemanse J; Sidharta PN
J Clin Pharmacol; 2017 Aug; 57(8):997-1004. PubMed ID: 28378883
[TBL] [Abstract][Full Text] [Related]
11. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans.
Bruderer S; Hopfgartner G; Seiberling M; Wank J; Sidharta PN; Treiber A; Dingemanse J
Xenobiotica; 2012 Sep; 42(9):901-10. PubMed ID: 22458347
[TBL] [Abstract][Full Text] [Related]
12. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
[TBL] [Abstract][Full Text] [Related]
13. Macitentan does not interfere with hepatic bile salt transport.
Treiber A; Äänismaa P; de Kanter R; Delahaye S; Treher M; Hess P; Sidharta P
J Pharmacol Exp Ther; 2014 Jul; 350(1):130-43. PubMed ID: 24769543
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.
Atsmon J; Dingemanse J; Shaikevich D; Volokhov I; Sidharta PN
Clin Pharmacokinet; 2013 Aug; 52(8):685-92. PubMed ID: 23568224
[TBL] [Abstract][Full Text] [Related]
15. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.
Bruderer S; Aänismaa P; Homery MC; Häusler S; Landskroner K; Sidharta PN; Treiber A; Dingemanse J
AAPS J; 2012 Mar; 14(1):68-78. PubMed ID: 22189899
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.
Sidharta PN; Lindegger N; Ulč I; Dingemanse J
J Clin Pharmacol; 2014 Mar; 54(3):291-300. PubMed ID: 24122797
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan.
Sidharta PN; Treiber A; Dingemanse J
Clin Pharmacokinet; 2015 May; 54(5):457-71. PubMed ID: 25860376
[TBL] [Abstract][Full Text] [Related]
18. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
Krause A; Zisowsky J; Dingemanse J
Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
[TBL] [Abstract][Full Text] [Related]
19. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
